The flinders sensitive line rats: A genetic animal model of depression

Neuroscience and Biobehavioral Reviews

Volumn 17, Issue 1, 1993, Pages 51-68

  Overstreet, David H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Cholinergic model; Construct and predictive validity; Depression; Face; FSLrat; REM sleep

Indexed keywords

CHOLINESTERASE INHIBITOR; DESIPRAMINE; IMIPRAMINE; MUSCARINIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR GENETICS; COGNITION; DEPRESSION; FACE; FEMALE; GENETIC MODEL; IMMOBILIZATION; INFORMATION PROCESSING; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REM SLEEP; REVIEW; WEIGHT REDUCTION;

ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; RATS; RATS, INBRED STRAINS; SUPPORT, NON-U.S. GOV'T;

EID: 0027513369     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(05)80230-1     Document Type: Article

References (178)

1. Depression The predisposing influence of stress
2. 2 and B-adrenergic receptor binding sites in the brain of suicide victims
3. Central control of anterior pituitary function
4. 2 binding sites in the frontal cortex of suicide victims and control subjects
5. CSF monoamine metabolites in melancholia
6. Muscarinic receptor subclassification and G-proteins: Significance for lithium action in affective disorders and for the treatment of extrapyramidal side effects of neuroleptics
7. Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system
8. Rat strain differences in response to dark pulse triggering of paradoxical sleep
9. Rolipram versus imipramine in inpatients with major, “minor” or atypical depressive disorder: A double blind double-dummy study aimed at testing a novel therapeutic approach
10. The cholinergic rapid eye movement sleep induction test with RS-86
11. Is the forced swimming test a suitable model for revealing antidepressant activity?
12. Mood and memory
13. Commentary on mood and memory
14. Depression, suicide and aggression in alcoholics and their relationship to plasma amino-acids
15. Nicotine dependence, major depression and anxiety in young adults
16. Contribution of the depressive perspective to memory function in depression
17. Down-regulation of β-adrenergic receptors following repeated injections of desmethylimipramine: Permissive role of serotonergic axons
18. Olfactory projective systems, drug and behavior: A review
19. Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories
20. Neuroendocrine regulation in depression. I: Limbic system-adrenocortical dysfunction
21. Long-term lithium treatment selectively reduced receptor-coupled inositol phospholipid hydrolysis in rat brain
22. Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress
23. Tolerance to low acetylcholinesterase levels: Modification of behavior without acute behavioral change
24. The biochemistry of affective disorders
25. A dopamine-5-Hydroxytryptamine link in the hypothalamic pathways which mediate heat loss in the rat
26. Changes in dopamine sensitivity in rats selectively bred for differences in cholinergic function
27. Biologic rhythm disorders, depression, and phototherapy
28. Mitogen-stimulated lymphocyte proliferation and pituitary hormones in major depression
29. Early development of muscarinic supersensitivity in a genetic animal model of depression
30. Diagnostic subgroups of affective disorders and their urinary excretion of catecholamine metabolites
31. Relation between the thermoregulatory effects of intracerebroventricularly injected dopamine noradrenaline and 5-HT in the rabbit
32. Lithium's effects on muscarine receptor binding parameters: A relationship to therapeutic eficacy?
33. Neurobiologic effects of bright light
34. Amitriptyline-induced supersensitivity of a central muscarinic mechanism: Lithium blocks amitriptyline-induced supersensitivity
35. Bright artificial light subsensitizes a central muscarinic mechanism
36. Bright light blocks amitriptyline induced cholinoceptor supersensitivity
37. The Flinders Sensitive Line exhibits enchanced thermic responsiveness to nicotine relative to the Sprague-Dawley rat
38. Cholinergic inhibition of self-stimulation behavior
39. Update on the dementia spectrum of derpression
40. Cholinergic modulation of adrenergic arousal in the developing rat
41. Biochemistry, anatomy, and pharmacology of GABA neurons
42. Neurotransmitters and pituitary function: Regulation of ACTH secretion
43. Catecholamine systems as the neural substrate for intracranial self-stimulation: A hypothesis
44. CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa
45. Genetics of affective illness
46. Motor effects of serotonin in the central nervous system
47. The serotonin/norepinephrine link in the brain. II. Role of serotonin in the regulation of beta-adrenoceptors in the low agonist affinity conformation
48. Successful separation of depressed, normal, and insomniac subjects by EEG sleep data
49. Age-related changes in sleep in depressed and normal subjects
50. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor
51. 1A receptors
52. Rate of forgetting in dementia and depression
53. The neural basis for violent behavior: Physiology and anatomy
54. Mechanism of action of antide-pressant treatments: Implications for the etiology and treatment of depressive disorders
55. ACTH and multisteroid responses to corticotropin-releasing factor in depressive illness: Relationship to multi-steroid response after ACTH stimulation and dexamethasone suppression
56. Clinical effects of the neurotropic-selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of preliminary reports
57. Reduction of immune function in life stress and depression
58. A cholinergic-adrenergic hypothesis of mania and depression
59. Antagonistic effects of physostigmine and methylphenidate in man
60. Increased vulnerability to cholinergic stimulation in affective disorder patients
61. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress
62. Acetylcholine mechanisms in affective disorders
63. Animal models of depression: Parallels and correlates to severe depression in humans
64. Retinohypothalamic projections in the hamster and rat demonstrated using cholera toxin
65. Animal models and human depressive disorders
66. Muscarinic binding in suicides
67. Cholinergic-dopaminergic interaction in experimental catalepsy
68. Evidence for a cholinergic role in haloperidol-induced catalepsy
69. Drug effects on active immobility responses: What they tell us about neurotransmitter systems and motor function
70. Brain serotonergic neurons: Their role in a form of dominance-subordination behavior in rats
71. Changes of acetylcholinesterase activity in three major brain areas and related changes in behavior following acute treatment with diisopropyl fluorophosphate
72. Phase advance theories for affective illnesses
73. Controlled trial of bright light for nonseasonal major depressive disorders
74. REM latency. A psychobiological marker for primary depressive disease
75. The olfactory bulbectomized rat as a model of depression
76. Studies on the role of brain cholinergic systems in the therapeutic mechanism and adverse effect of electroconvulsive therapy and lithium
77. 5-HT1A receptor function in depression: Effect of chronic amitriptyline treatment
78. Upregulation of gamma amino butyric acid (GABA)B binding sites in rat frontal cortex. A common action of repeated administration of different classes of antidepressants and footshock
79. GABA and affective disorders
80. Learned helplessness and animal models of depression. Prog Neuropsychopharmacol
81. The effect of antidepressant drugs on dominance behavior in rats competing for food
82. Increased serotonin and beta-adrenergic receptor binding in the frontal cortices of suicide victims
83. Cholinergic-dopaminergic interactions and the mechanisms of action of antidepressants
84. Cognitive functioning in the affective disorders
85. Animal models of depression: An overview
86. The serotonin hypothesis of depression
87. Human brain receptor alterations in suicide victims
88. Increased 5-HT-2 receptor function as measured by serotonin-stimulated phosphoinositide hydrolysis in platelets of depressed patients
89. GABA, depression and the mechanism of action of antidepressant drugs: A neuroendocrine approach
90. The role of corticotropin-releasing factor in the pathogenesis of major depression
91. Reduced corticotropin-releasing factor (CRF) binding sites in the frontal cortex of suicides
92. Effects of cholinergic agonists and antagonists on self-stimulation behavior
93. Combined cholinergic and serotonergic denervation of the forebrain produced severe deficits in a spatial learning task in the rat
94. Measuring cholinergic sensitivity: I. Arecoline effects in bipolar patients
95. Selective breeding for increased cholinergic function: Development of a new animal model of depression
96. Animal models for psychiatric illness
97. Correlations of ethanol-induced hypothermia in FSL and FRL rats with hypothermia induced by other drugs
98. Commentary: A behavioral, psychopharmacological and neurochemical update on the Flinders Sensitive Line rat, a potential animal model of depression
99. Genetic animal models of endogenous depression
100. A cholinergic supersensitivity model of depression
101. Impaired active avoidance performance in rats with cholinergic supersensitivity: Its reversal with chronic imipramine
102. Selective breeding for sensitivity to DFP. Effects of cholinergic agonists and antagonists
103. Enhanced elevation of corticosterone following arecoline administration to rats selectively bred for increased cholinergic function
104. Effects of bright light on responsiveness to a muscarinic agonist in rats selectively bred for endogenously increased cholinergic function
105. Stress-induced immobility in rats with cholinergic supersensitivity
106. Impaired active avoidance responding in rats selectively bred for increased cholinergic function
107. Behavioral profiles of rat strains which prefer or do not prefer ethanol
108. Genetic animal models of depression and ethanol preference provide support for cholinergic and serotonergic involvement in depression and alcoholism
109. Selective breeding for differences in cholinergic function: Pre-and post-synaptic mechanisms involved in sensitivity to the anticholinesterase, DFP
110. Genetic and pharmacological models of cholinergic supersensitivity and affective disorders
111. Selective breeding for differences in cholinergic function Biometrical genetic analysis of muscarinic responses
112. Selective breeding for sensitivity to the anticholinesterase, DFP
113. Antidepressant effects of rolipram in a genetic animal of depression: Cholinergic supersensitivity and weight gain
114. Preclinical and clinical studies with corticotropin-releasing factor: Implications for affective disorders
115. Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity
116. Validation of open-closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
117. Enhanced benzodiazepine responsiveness in rats with increased cholinergic function
118. GABAergic modulation of learned helplessness
119. The effect of lesions of the locus coeruleus and treatment with drugs affecting brain noradrenergic neurotransmission on dominant-subordinate behavior in rat competing for water
120. Behavioral despair
121. L-tryptophan in mania: Contribution to a permissive hypothesis of affective disorders
122. Monoaminergic control of affective aggression
123. Effects of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains
124. Enhanced affective aggression in genetically bred hypercholinergic rats
125. Effects of calcium channel inhibitors on the hypothermic response to oxotremorine in normo and hypercholinergic rats
126. Effects of acute and chronic stressors on saccharin preference in hypercholinergic rats
127. Biochemical and pharmacological evidence for central cholinergic regulation of shock-induced aggression
128. B-endorphin hypersecretion in depression: Possible cholinergic mechanisms
129. Differential mood effects of arecoline in depressed patients and normal volunteers
130. A study to assess the anticholinergic activity of rolipram in health elderly volunteers
131. Mechanisms underlying sensitivity to organophosphorus anticholinesterase compounds administered acutely or chronically
132. Selective breeding for sensitivity to DFP. Generalization of effects beyond criterion variables
133. Disorders of feeling: Affective disorders
134. Dopaminergic and cholinergic influences on motor behavior in chickens
135. The catecholamine hypothesis of affective disorders: A review of supporting evidence
136. Altered behavioral sensitivity to serotonergic agonists in an animal model of depressive disorders: Receptor binding correlates and cholinergic-serotonergic systems interaction
137. Regulation of muscarinic receptors in two lines of rats genetically selected for differential cholinergic sensitivity
138. Absence of anxiety in an animal model of depression with cholinergic supersensitivity
139. Effects of intracerebroventricular administration of site selective muscarinic drugs in rats genetically selected for differing cholinergic sensitivity
140. Immobility-reducing effects of antidepressants in a genetic animal of depression
141. 3-Methoxy-4-hydroxyphenylethyleneglycol in depression
142. Additivity of neurochemical changes in learned helplessness and imipramine
143. Acetylcholine and the regulation of REM sleep — Basic mechanisms and clinical implications for affective illness and narcolepsy
144. Increased REM sleep in rats selectively bred for cholinergic hyperactivity
145. Dietary lithium blunts oxotremorine-induced hypothermia in a genetic animal model of depression
146. Failure of dietary lithium to alter immobility in an animal model of depression
147. Circadian rhythm of core body temperature is phase-advanced in a rodent model of depression
148. Effects of sleep deprivation on sleepiness and increased REM sleep in rats selectively bred for cholinergic hyperactivity
149. Free-running period of the circadian drinking rhythm is shorter in rats with an upregulated central cholinergic system
150. Studies on the possible relationship of brain proteins to behavioral sensitivity to DFP
151. The association of supersensitive cholinergic REM induction and affective illness within pedigrees
152. Benzodiazepine receptors in the central nervous system
153. Depression, the immune system and health and illness
154. Mode of action of antidepressant drugs
155. New perspectives on the molecular pharmacology of affective disorders
156. Monoamines and abnormal behavior. A multi-amninergic perspective
157. Potential antidepressant activity of rolipram and other selective cyclic 3′,5′-monophosphate phosphodiesterase inhibitors
158. Dysbalance of neuronal second messenger function in aetiology of affective disorders: A pathophysiological concept hypothesizing defects beyond first messenger receptors
159. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors
160. Absence of anticholinergic sensitivity of rolipram, an antidepressant with a novel mechanism of action, in three different animal models in vivo
161. Selective breeding for increased cholinergic function: Psychopharmacological evidence for altered serotonergic sensitivity
162. Circadian rhythm mechanism in affective illness and in antidepressant drug action
163. Circadian rhythm disturbances in manic-depressive illness
164. Behavioral depression produced by an uncontrollable stressor: Relationship to norepinephrine, dopamine and serotonin levels in various regions of rat brain
165. Dopamine and depression: A review of recent evidence
166. The validity of animal models of depression
167. Animal models of depression: An overview
168. Animal models as simulations of depression
169. Reduction of sucrose preference by chronic mild stress and its restoration by a tricyclic antidepressant
170. Catecholamine theories of reward. A critical review
171. Motor activity and affective illness. The relationship of amplitude and temporal distribution to changes in affective state
172. Presynaptic modulation of transmitter release by nicotinic receptors
173. 2 receptor changes in major depression
174. Region specific reduction of intracranial self-stimulation after uncontrollable stress: Possible effects on reward processes